Targeting Helicobacter pylori in gastric carcinogenesis

Bibliography

• PARKIN DM: Global cancer statistics in the year 2000. Lancet Oncol. (2001) 2(9):533-543.
   PubMed Web of Science ®Google Scholar
• HAENSZEL W, KURIHARA M, SEGI M, LEE RK: Stomach cancer among Japanese in Hawaii. J. Natl. Cancer Inst. (1972) 49:969-988.
   PubMed Web of Science ®Google Scholar
• MARSHALL BJ, WARREN R: Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet (1984) 1(8390):1311-1315.
   PubMed Web of Science ®Google Scholar
• SUERBAUM S, MICHETTI P: Helicobacter infection. N. Engl. J. Med. (2002) 347:1175-1186.
   PubMed Web of Science ®Google Scholar
• PEREZ-PEREZ GI, DWORKIN BM, CHODOS JE, BLASER MJ: Campylobacter pylori antibodies in humans. Ann. Intern. Med. (1988) 109:11-17.
   PubMed Web of Science ®Google Scholar
• D’ELIOS MM, MANGHETTI M, DE CARLI M et al.: T helper 1 effector cells specific for Helicobacter pylori in the gastric antrum of patients with peptic ulcer disease. J. Immunol. (1997) 158:962-967.
   Google Scholar
• EVERHART JE, KRUSZON-MORAN D, PEREZ-PEREZ GI, TRALKA TS, MCQUILLAN G: Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States. J. Infect. Dis. (2000) 181(4):1359-1363.
   PubMed Web of Science ®Google Scholar
• MALATY HM, GRAHAM DY: Importance of childhood socioeconomic status on the current prevalence of Helicobacter pylori infection. Gut (1994) 35(6):742-745.
   PubMed Web of Science ®Google Scholar
• DANESH J: Helicobacter pylori infection and gastric cancer: systematic review of the epidemiological studies. Aliment. Pharmacol. Ther. (1999) 13:851-856.
   PubMed Web of Science ®Google Scholar
• HUANG JQ, SRIDHAR S, CHEN Y, HUNT RH: Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology (1998) 114:1169-1179.
   PubMed Web of Science ®Google Scholar
• ESLICK GD, LIM LL, BYLES JE, XIA HH, TALLEY NJ: Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am. J. Gastroenterol. (1999) 94:2373-2379.
   PubMed Web of Science ®Google Scholar
• PRITCHARD DM, PRZENMECK SM: Review article: How useful are the rodent animal models of gastric adenocarcinoma? Aliment. Pharmacol. Ther. (2004) 19:841-859.
   Google Scholar
• CORREA P: Helicobacter pylori and gastric carcinogenesis. Am. J. Surg. Pahol. (1995) 19(Suppl. 1):S37-S43.
   Google Scholar
• YOU WC, LI JY, BLOT WJ et al.: Evolution of precancerous lesions in a rural Chinese population at high risk of gastric cancer. Int. J. Cancer (1999) 83:615-619.
   PubMed Web of Science ®Google Scholar
• CORREA P: Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. (1992) 52:6735-6740.
   Google Scholar
• KAMANGAR F, QIAO YL, BLASER MJ et al.: Helicobacter pylori and oesophageal and gastric cancers in a prospective study in China. Br. J. Cancer (2007) 96(1):172-176.
   PubMed Web of Science ®Google Scholar
• KAMANGAR F, DAWSEY SM, BLASER MJ et al.: Opposing risks of gastric cardia and noncardia gastric adenocarcinoma-associated Helicobacter pylori seropositivity. J. Natl. Cancer Inst. (2006) 98(20):1445-1452.
   PubMed Web of Science ®Google Scholar
• BLASER MJ: An endangered species in the stomach. Sci. Am. (2005) 292(2):38-45.
   PubMedGoogle Scholar
• UEMURA N, OKAMOTO S, YAMAMOTO S et al.: Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. (2001) 345:784-789.
   PubMed Web of Science ®Google Scholar
• ZUCCA E, BERTONI F, ROGGERO E et al.: Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach. N. Engl. J. Med. (1998) 338:804-810.
   PubMed Web of Science ®Google Scholar
• BLASER MJ, PARSONNET J: Parasitism by the ‘slow’ bacterium Helicobacter pylori leads to altered gastric homeostasis and neoplasia. J. Clin. Invest. (1994) 94(1):4-8.
   Google Scholar
• DOGLIONI C, WOTHERSPOON AC, MOSCHINI A, DE BONI M, ISAACSON PG: High incidence of primary gastric lymphoma in northeastern Italy. Lancet (1992) 339:834-835.
   PubMed Web of Science ®Google Scholar
• Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Human. IARC. Monogr. Eval. Carcinog. Risks Hum. Lyon, France, 7-14 June (1994) 61:1-241.
   PubMedGoogle Scholar
• BLASER MJ, ATHERTON JC: Helicobacter pylori persistence: biology and disease. J. Clin. Invest. (2004) 113(3):321-333.
   PubMed Web of Science ®Google Scholar
• BAIK SC, YOUN HS, CHUNG MH et al.: Increased oxidative DNA damage in Helicobacter pylori-infected human gastric mucosa. Cancer Res. (1996) 56(6):1279-1282.
   PubMed Web of Science ®Google Scholar
• SHIRIN H, WEINSTEIN IB, MOSS SF: Effects of H. pylori infection of gastric epithelial cells on cell cycle control. Front. Biosci. (2001) 6:E104-E118.
   Google Scholar
• MARTIN JH, POTTHOFF A, LEDIG S et al.: Effect of H. pylori on the expression of TRAIL, FasL and their receptor subtypes in human gastric epithelial cells and their role in apoptosis. Helicobacter. (2004) 9:371-386.
   Google Scholar
• RUDI J, KUCK C, MAIWALD M et al.: Involvement of the CD95 (APO-1/Fas) receptor and ligand system in Helicobacter pylori-induced gastric epithelial apoptosis. J. Clin. Invest. (1998) 102(8):1506-1514.
   PubMed Web of Science ®Google Scholar
• MOSS SF, SORDILLO EM, ABDALLAH AM et al.: Increased gastric epithelial cell apoptosis associated with colonization with cagA+ Helicobacter pylori strains. Cancer Res. (2001) 61(4):1406-1411.
   PubMed Web of Science ®Google Scholar
• PEEK RM JR, MOSS SF, THAM KT et al.: Helicobacter pylori cagA+ strains and dissociation of gastric epithelial cell proliferation from apoptosis. J. Nat. Cancer Inst. (1997) 89(12):863-868.
   PubMedGoogle Scholar
• TOMB JF, WHITE O, KERIAVAGE AR et al.: The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature (1997) 388:539-547.
   PubMed Web of Science ®Google Scholar
• ALM RA, LING LS, MOIR DT et al.: Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature (1999) 397:176-180.
   PubMed Web of Science ®Google Scholar
• SALAMA N, GUILLEMIN K, MCDANIEL TK, SHERLOCK G, TOMPKINS L, FALKOW S: A whole-genome microarray reveals genetic diversity among Helicobacter pylori strains. Proc. Natl. Acad. Sci. USA (2000) 97(26):14668-14673.
   PubMed Web of Science ®Google Scholar
• FAN X, GUNASENA H, CHENG Z et al.: Helicobacter pylori urease binds to class II MHC on gastric epithelial cells and induces their apoptosis. J. Immunol. (2000) 165:1918-1924.
   PubMedGoogle Scholar
• PEEK RM JR, CRATREE JE: Helicobacter infection and gastric neoplasia. J. Pathol. (2006) 208:233-248.
   PubMedGoogle Scholar
• MONTEIRO MA, CHAN KH, RASKO DA et al.: Simultaneous expression of Type 1 and Type 2 Lewis blood group antigens by Helicobacter pylori lipopolysaccharides. Molecular mimicry between H. pylori lipopolysaccharides and human gastric epithelial cell surface glycoforms. J. Biol. Chem. (1998) 273:11533-11543.
   PubMed Web of Science ®Google Scholar
• CENSINI S, LANGE C, XIANG Z et al.: cag, a pathogenicity island of Helicobacter pylori, encodes Type I-specific and disease-associated virulence factors. Proc. Natl. Acad. Sci. USA (1996) 93:14648-14653.
   PubMed Web of Science ®Google Scholar
• HUANG JQ, ZHENG GF, SUMANAC K, IRVINE EJ, HUNT RH: Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology (2003) 125:1636-1644.
   PubMed Web of Science ®Google Scholar
• ASAHI M, AZUMA T, ITO S et al.: Helicobacter pylori CagA protein can be tyrosine phosphorylated in gastric epithelial cells. J. Exp. Med. (2000) 191:593-602.
   PubMed Web of Science ®Google Scholar
• ODENBREIT S, PULS J, SEDLMAIER B, GERLAND E, FISCHER W, HAAS R: Translocation of Helicobacter pylori CagA into gastric epithelial cells by Type IV secretion. Science (2000) 287:1497-1500.
   PubMed Web of Science ®Google Scholar
• STEIN M, RAPPUOLI R, COVACCI A: Tyrosine phosphorylation of the Helicobacter pylori CagA antigen after cag-driven host cell translocation. Proc. Natl. Acad. Sci. USA (2000) 97:1263-1268.
   PubMed Web of Science ®Google Scholar
• HIGASHI H, TSUTSUMI R, MUTO S et al.: SHP-tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science (2002) 295:683-686.
   PubMed Web of Science ®Google Scholar
• TSUTSUMI R, HIGASHI H, HIGUCHI M, OKADA M, HATAKEYAMA M: Attenuation of Helicobacter pylori CagA SHP-2 signaling by interaction between CagA and C-terminal Src kinase. J. Biol. Chem. (2003) 278:3664-3670.
   PubMed Web of Science ®Google Scholar
• BOURZAC KM, GUILLEMIN K: Helicobacter pylori-host cell interactions mediated by Type IV secretion. Cell. Microbiol. (2005) 7(7):911-919.
   Google Scholar
• KEATES S, SOUGIOULTZIS S, KEATES AC et al.: cag+ Helicobacter pylori induce transactivation of the epidermal growth factor receptor in AGS gastric epithelial cells. J. Biol. Chem. (2001) 276:48127-48134.
   PubMed Web of Science ®Google Scholar
• AZUMA T, YAMAZAKI S, YAMAKAWA A et al.: Association between diversity in the SRC homology 2 domain-containing tyrosine phosphatase binding site of Helicobacter pylori CagA protein and gastric atrophy and cancer. J. Infect. Dis. (2004) 189:820-827.
   PubMed Web of Science ®Google Scholar
• VIALA J, CHAPUT C, BONECA IG et al.: Nod1 responds to peptidogylcan delivered by the Helicobacter pylori cag pathogenicity island. Nat. Immunol. (2004) 5:1166-1174.
   PubMed Web of Science ®Google Scholar
• ATHERTON JC, CAO P, PEEK RM JR, TUMMURU MK, BLASER MJ, COVER TL: Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. Association of specific vacA types with cytotoxin production and peptic ulceration. J. Biol. Chem. (1995) 270:17771-17777.
   PubMed Web of Science ®Google Scholar
• MONTECUCCO C, DE BERNARD M: Immunosuppressive and proinflammatory activities of the VacA toxin of Helicobacter pylori. J. Exp. Med. (2003) 198:1767-1771.
   Google Scholar
• BONCRISTIANO M, PACCANI SR, BARONE S et al.: The Helicobacter pylori vacuolating toxin inhibits T cell activation by two independent mechanisms. J. Exp. Med. (2003) 198:1887-1897.
   PubMed Web of Science ®Google Scholar
• COVER TL, KRISHNA US, ISRAEL DA, PEEK RM JR: Induction of gastric epithelial cell apoptosis by Helicobacter pylori vacuolating cytotoxin. Cancer Res. (2003) 63:951-957.
   Google Scholar
• MOLINARI M, SALIO M, GALLI C et al.: Selective inhibition of Ii-dependent antigen presentation by Helicobacter pylori toxin VacA. J. Exp. Med. (1998) 187:135-140.
   PubMed Web of Science ®Google Scholar
• GEBERT B, FISCHER W, WEISS E, HOFFMANN R, HAAS R: Helicobacter pylori vacuolating cytotoxin inhibits T lymphocyte activation. Science (2003) 301(5636):1099-1102.
   PubMed Web of Science ®Google Scholar
• HANSSON LE, NYREN O, HSING AW et al.: The risk of stomach cancer in patients with gastric and duodenal ulcer disease. N. Engl. J. Med. (1996) 335:242-249.
   PubMed Web of Science ®Google Scholar
• EL-OMAR EM, CARRINGTON M, CHOW WH et al.: Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature (2000) 404:398-402.
   PubMed Web of Science ®Google Scholar
• MACHADO JC, PHAROAH P, SOUSA S et al.: Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology (2001) 121:823-829.
   PubMed Web of Science ®Google Scholar
• FIGUEIREDO C, MACHADO JC, PHAROAH P et al.: Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J. Natl. Cancer Inst. (2002) 94:1680-1687.
   PubMed Web of Science ®Google Scholar
• EL-OMAR EM: Role of host genes in sporadic gastric cancer. Best Pract. Res. Clin. Gastro. (2006) 20(4):675-686.
   PubMed Web of Science ®Google Scholar
• STARZYNSKA T, FERENC K, WEX T et al.: The association between the interleukin-1 polymorphisms and gastric cancer risk depends on the family history of gastric carcinoma in the study population. Am. J. Gastroenterol. (2006) 101(2):248-254.
   PubMed Web of Science ®Google Scholar
• PERRI F, PIEPOLI A, BONVICINI C et al.: Cytokine gene polymorphisms in gastric cancer patients from two Italian areas at high and low cancer prevalence. Cytokine (2005) 30(5):293-302.
   PubMedGoogle Scholar
• SANDULEANU S, JONKERS D, DE BRUINE A, HAMEETEMAN W, STOCKBRUGGER RW: Changes in gastric mucosa and luminal environment during acid-suppressive therapy: a review in depth. Dig. Liver Dis. (2001) 33(8):707-719.
   PubMedGoogle Scholar
• HOUGHTON J, STOICOV C, NOMURA S et al.: Gastric cancer originating from bone marrow-derived cells. Science (2004) 306(5701):1568-1571
   PubMed Web of Science ®Google Scholar
• MOSS SF, BLASER MJ: Mechanisms of disease: Inflammation and origins of cancer. Nat. Clin. Pract. Oncol. (2005) 2(2):90-97.
   PubMedGoogle Scholar
• NARDONE G, ROCCO A, MALFERTHEINER P: Helicobacter pylori and molecular events in precancerous gastric lesion. Aliment. Pharmacol. Ther. (2004) 20:261-270.
   Google Scholar
• GRAZIANO F, ARDUINI F, RUZZO A et al.: Prognostic analysis of E-cadherin gene promoter hypermethylation in patients with surgically resected, node-positive, diffuse gastric cancer. Clin. Cancer Res. (2004) 10(8):2784-2789.
   Google Scholar
• SUGIMURA T, USHIJIMA T: Genetic and epigenetic alterations in carcinogenesis. Mutat. Res. (2000) 462:235-246.
   PubMed Web of Science ®Google Scholar
• VERMA M, SRIVASTAVA S: Epigenetics in cancer: implications for early detection and prevention. Lancet Oncol. (2002) 3:755-763.
   PubMed Web of Science ®Google Scholar
• CHAN AO, PENG JZ, LAM SK et al.: Eradication of Helicobacter pylori infection reverses E-cadherin promoter hypermethylation. Gut (2006) 55(4):463-468.
   PubMed Web of Science ®Google Scholar
• MAEKITA T, NAKAZAWA K, MIHARA M et al.: High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosa and its possible association with gastric cancer risk. Clin. Cancer Res. (2006) 12:989-995.
   PubMed Web of Science ®Google Scholar
• HMADCHA A, BEDOYA FJ, SOBRINO F, PINTADO E: Methylation-dependent gene silencing induced by interleukin 1beta via nitric oxide production. J. Exp. Med. (1999) 190:1595-1604.
   PubMed Web of Science ®Google Scholar
• TAMURA G: Promoter methylation status of tumor suppressor and tumor-related genes in neoplastic and non-neoplastic gastric epithelia. Histol. Histopathol. (2004) 19:221-228.
   PubMed Web of Science ®Google Scholar
• USHIJIMA T, NAKAJIMA T, MAEKITA T: DNA methylation as a marker for the past and future. J. Gastroenterol. (2006) 41:401-407.
   PubMed Web of Science ®Google Scholar
• FORBES GM, WARREN JR, GLASER ME, CULLEN DJ, MARSHALL BJ, COLLINS BJ: Long-term follow-up of gastric histology after Helicobacter pylori eradication. J. Gastroenterol. Hepatol. (1996) 11:670-673.
   PubMed Web of Science ®Google Scholar
• HARUMA K, MIHARA M, OKAMOTO E et al.: Eradication of Helicobacter pylori increases gastric acidity in patients with atrophic gastritis of the corpus-evaluation of 24-h pH monitoring. Aliment. Pharmacol. Ther. (1999) 13:155-162.
   PubMed Web of Science ®Google Scholar
• MACONI G, LAZZARONI M, SANGALETTI O, BARGIGGIA S, VAGO L, BIANCHI PORRO G: Effect of Helicobacter pylori eradication on gastric histology, serum gastrin and pepsinogen I level, and gastric emptying in patients with gastric ulcer. Am. J. Gastroenterol. (1997) 92:1844-1848.
   PubMed Web of Science ®Google Scholar
• NARDONE G, STAIBANO S, ROCCO A et al.: Effect of Helicobacter pylori infection and its eradication on cell proliferation, DNA status, and oncogene expression in patients with chronic gastritis. Gut (1999) 44:789-799.
   PubMed Web of Science ®Google Scholar
• FORMAN D: Lessons from ongoing intervention studies. In: Helicobacter pylori. Basic mechanisms to clinical cure. Hunt RH, Tytgat GN (Eds). Dordrecht: Kluwer Academic Publishers (1998):354-361.
   Google Scholar
• FUCCIO L, ZAGARI RM, MINARDI ME, BAZZOLI F: Systematic review: Helicobacter pylori eradication for the prevention of gastric cancer. Aliment. Pharmacol. Ther. (2007) 25:133-141.
   PubMed Web of Science ®Google Scholar
• CORREA P, FONTHAM ET, BRAVO JC et al.: Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J. Natl. Cancer Inst. (2000) 92:1881-1888.
   PubMed Web of Science ®Google Scholar
• WONG BC, LAM SK, WONG WM et al.: Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: A randomized controlled trial. JAMA (2004) 291:187-194.
   PubMed Web of Science ®Google Scholar
• YOU WC, BROWN LM, ZHANG L et al.: Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J. Nat. Cancer Inst. (2006) 98:974-983.
   PubMed Web of Science ®Google Scholar
• LEUNG WK, LIN SR, CHING JY et al.: Factors predicting progression of gastric intestinal metaplasia: results of a randomized trial on Helicobacter pylori eradication. Gut (2004) 53:1244-1249.
   PubMed Web of Science ®Google Scholar
• ZHOU L, SUNG JJ, LIN S et al.: A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chin. Med. J. (Engl.) (2003) 116:11-14.
   PubMed Web of Science ®Google Scholar
• PARSONNET J, HARRIS RA, HACK HM, OWENS DK: Modeling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet (1996) 348:150-154.
   PubMed Web of Science ®Google Scholar
• MALFERTHEINER P, MEGRAUD F, O’MORAIN C et al.: Current concepts in the management of Helicobacter pylori infection-The Maastricht III Consensus Report. Gut (2007) Epub ahead of print.
   Google Scholar
• MEYER JM, SILLIMAN NP, WANG W et al.: Risk factors for Helicobacter pylori resistance in United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. Ann. Intern. Med. (2002) 136:13-24.
   PubMed Web of Science ®Google Scholar
• GISBERT JP, CALVET X, BUJANDA L, MARCOS S, GISBERT JL, PAJARES JM: ‘Rescue’ therapy with rifabutin after multiple Helicobacter pylori treatment failures. Helicobacter. (2003) 8:90-94.
   PubMed Web of Science ®Google Scholar
• XIA HH, YU WONG BC, TALLEY NJ, LAM SK: Alternative and rescue treatment regimens for Helicobacter pylori eradication. Expert Opin. Pharmacother. (2002) 3:1301-1311
   Google Scholar
• VAIRA D, ZULLO A, VAKIL N et al.: Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann. Intern. Med. (2007) 146(8):556-563.
   PubMed Web of Science ®Google Scholar
• FRANCAVILLA R, LIONETTI E, CASTELLANETA SP et al.: Improved efficacy of 10-day sequential treatment for Helicobacter pylori eradication in children: a randomized trial. Gastroenterology (2005) 129(5):1414-1419.
   PubMed Web of Science ®Google Scholar
• SCHILLER JT, LOWY DR: Prospect for cervical cancer prevention by human papillomavirus vaccination. Cancer Res. (2006) 66:10229-10232.
   PubMed Web of Science ®Google Scholar
• GRAHAM DY, OPEKUN AR, OSATO MS et al.: Challenge model for Helicobacter pylori infection in human volunteers. Gut (2004) 53:1235-1243.
   PubMed Web of Science ®Google Scholar
• SUTTON P: Progress in vaccination against Helicobacter pylori. Vaccine (2001) 19:2286-2290.
   PubMedGoogle Scholar
• MOHAMMADI M, NEDRUD J, REDLINE R, LYCKE N, CZINN SJ: Murine CD4 T-cell response to Helicobacter infection: TH1cells enhance gastritis and TH2 cells reduce bacterial load. Gastroenterology (1997) 113:1848-1857.
   PubMed Web of Science ®Google Scholar
• RAD R, BRENNER L, BAUER S et al.: CD25+/Foxp3+ T cells regulate gastric inflammation and Helicobacter pylori colonization in vivo. Gastroenterology (2006) 131(2):525-537.
   PubMed Web of Science ®Google Scholar
• MICHETTI P, KREISS C, KOTLOFF KL et al.: Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology (1999) 116:804-812.
   PubMed Web of Science ®Google Scholar
• ARORA S, CZINN SJ: Vaccination as a method of preventing Helicobacter pylori-associated gastric cancer. Cancer Epidemiol. Biomarkers Prev. (2005) 14(8):1890-1891.
   Google Scholar
• SUGIYAMA A, MARUTA F, IKENO T et al.: Helicobacter infection enhances N-methyl-N-nitrosourea-induced stomach carcinogensis in the Mongolian gerbil. Cancer Res. (1998) 58:2067-2069.
   PubMed Web of Science ®Google Scholar
• WATANABE T, TADA M, NAGAI H, SASAKI S, NAKAO M: Helicobacter pylori infection induces gastric cancer in mongolian gerbils. Gastroenterology (1998) 115:642-648
   PubMed Web of Science ®Google Scholar
• HONDA S, FUJIOKA T, TOKIEDA M, SATOH R, NISHIZONO A, NASU M: Development of Helicobacter-induced gastric carcinoma in Mongolian gerbils. Cancer Res. (1998) 58:4255-4259.
   PubMed Web of Science ®Google Scholar
• SHIMIZU N, IKEHARA Y, INADA K et al.: Eradication diminishes enhancing effects of Helicobacter pylori infection on glandular stomach carcinogenesis in Mongolian gerbil. Cancer Res. (2000) 60:1512-1514.
   PubMed Web of Science ®Google Scholar
• WANG WH, HUANG JQ, ZHENG GF, LAM SK, KARLBERG J, WONG BC: Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J. Natl. Cancer Inst. (2003) 95:1784-1791.
   PubMedGoogle Scholar
• SUNG JJ, LEUNG WK, GO MY et al.: Cyclooxgenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am. J. Pathol. (2000) 157:729-735.
   PubMed Web of Science ®Google Scholar
• FUTAGAMI S, SUZUKI K, HIRATSUKA T et al.: Celecoxib inhibits Cdx2 expression and prevents gastric cancer in Helicobacter pylori-infected Mongolian gerbils. Digestion (2006) 74:187-198.
   Google Scholar
• NAM KT, HAHM KB, OH SY et al.: The selective cyclooxygenase-2 inhibitor nimesulide prevents Helicobacter pylori-associated gastric cancer development in a mouse model. Clin. Cancer Res. (2004) 10(23):8105-8113.
   PubMedGoogle Scholar
• LEUNG WL, NG EK, CHANG FK et al.: Effect of long-term rofecoxib on gastric intestinal metaplasia: results of randomized controlled trial. Clin. Cancer Res. (2006) 12:4766-4772.
   Google Scholar
• MUKHERJEE D, NISSEN SE, TOPOL EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA (2001) 286:954-959.
   PubMed Web of Science ®Google Scholar
• GRAHAM DY, SHIOTANI A: The time to eradicate gastric cancer is now. Gut (2005) 54:735-738.
   PubMed Web of Science ®Google Scholar